Bymetric
UK company intelligence
Company Active LTD

Company profile

Twistdx Limited

Versatile Isothermal DNA/RNA Amplification by TwistDx

Discover Recombinase Polymerase Amplification - The versatile PCR replacement. RPA is a rapid and robust, low temperature DNA and RNA amplification technology | TwistDx

CRN
04523987
Founded
2002
Age
23

Overview

Legal name
TWISTDX LIMITED
Region
South East England
Registered address
ABBOTT HOUSE VANWALL BUSINESS PARK
VANWALL ROAD
MAIDENHEAD
UNITED KINGDOM
SL6 4XE
Insolvency history
No

Corporate ownership

Updated 06 Jun 2026 16:52

2 levels 1 ultimate controller
1
Company Active LTD
Twistdx Limited
CRN 04523987
2
Direct controller Active LTD
Alere UK Holdings Limited
CRN 04267530
3
Ultimate controller
08142220
CRN 08142220

Company events

Reference milestones and recent Companies House filing stream events.

6 events
30 Sep
2026

Accounts due

Accounts Due

Next accounts due date

12 Jun
2026

Confirmation statement due

Confirmation Due

Next confirmation statement due date

29 May
2025

Confirmation statement filed

Confirmation

Last confirmation statement made up date

31 Dec
2024

Accounts filed

Accounts

Last accounts made up date

08 Oct
2024

Accounts With Accounts Type Small

Accounts PDF pending

AA | Transaction MzQzODE1MzU5MmFkaXF6a2N4 | Paper/PDF filed

Published 09 Oct 2024 06:32

02 Sep
2002

Incorporated

Inception

Company registered at Companies House

Public funding

3 awards
First funded
2010
Funded years
2010
Age at first award
7 years

Projects

2010 Feasibility Studies Lead participant

Feasibility of using recombinase polymerase amplification for point of care diagnosis of Mycoplasma pneumoniae a major cause of community acquired pneumonia

1 Oct 2010 to 30 Sep 2011

Awarded
£67,500
Total cost £90,000

Awaiting Public Summary

2010 Feasibility Studies Lead participant

Development of isothermal amplification method for point of care detection of classical swine fever virus african fever virus and avain influenza virus

1 Aug 2010 to 31 Oct 2011

Awarded
£75,000
Total cost £100,000

Awaiting Public Summary

2010 Feasibility Studies Lead participant

Feasibility of using recombinase polymerase amplification for a Rapid Point of Care Test for Tuberculosis

1 Aug 2010 to 31 Aug 2011

Awarded
£51,675
Total cost £74,500

Awaiting Public Summary

Product types

Feasibility Studies